WO2002042480A3 - Modified vaccinia ankara virus variant - Google Patents

Modified vaccinia ankara virus variant Download PDF

Info

Publication number
WO2002042480A3
WO2002042480A3 PCT/EP2001/013628 EP0113628W WO0242480A3 WO 2002042480 A3 WO2002042480 A3 WO 2002042480A3 EP 0113628 W EP0113628 W EP 0113628W WO 0242480 A3 WO0242480 A3 WO 0242480A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
modified vaccinia
vaccinia ankara
patients
ankara virus
Prior art date
Application number
PCT/EP2001/013628
Other languages
French (fr)
Other versions
WO2002042480A2 (en
Inventor
Paul Chaplin
Paul Howley
Christine Meisinger
Original Assignee
Bavarian Nordic Res Inst As
Paul Chaplin
Paul Howley
Christine Meisinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002042480(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic Res Inst As, Paul Chaplin, Paul Howley, Christine Meisinger filed Critical Bavarian Nordic Res Inst As
Priority to ES01991753.3T priority Critical patent/ES2256323T5/en
Priority to UA2003054618A priority patent/UA76731C2/en
Priority to PL361459A priority patent/PL212047B1/en
Priority to AU3163902A priority patent/AU3163902A/en
Priority to DE60116371.0T priority patent/DE60116371T3/en
Priority to CA2421151A priority patent/CA2421151C/en
Priority to BRPI0115533A priority patent/BRPI0115533B8/en
Priority to JP2002545184A priority patent/JP4421188B2/en
Priority to NZ524661A priority patent/NZ524661A/en
Priority to IL15471201A priority patent/IL154712A0/en
Priority to SI200130512T priority patent/SI1335987T2/en
Priority to AT01991753T priority patent/ATE314483T2/en
Priority to EP01991753.3A priority patent/EP1335987B2/en
Priority to MXPA03002513A priority patent/MXPA03002513A/en
Priority to KR1020037006970A priority patent/KR100830295B1/en
Priority to HU0400685A priority patent/HU230198B1/en
Priority to EEP200300173A priority patent/EE05680B1/en
Priority to AU2002231639A priority patent/AU2002231639B2/en
Publication of WO2002042480A2 publication Critical patent/WO2002042480A2/en
Publication of WO2002042480A3 publication Critical patent/WO2002042480A3/en
Priority to IL154712A priority patent/IL154712A/en
Priority to US10/418,854 priority patent/US7097842B2/en
Priority to US10/440,073 priority patent/US7189536B2/en
Priority to US10/439,439 priority patent/US6913752B2/en
Priority to US10/439,953 priority patent/US6761893B2/en
Priority to NO20032309A priority patent/NO337867B1/en
Priority to HK04102348.1A priority patent/HK1059453A1/en
Priority to US11/071,741 priority patent/US7445924B2/en
Priority to US11/112,438 priority patent/US7628980B2/en
Priority to US11/198,557 priority patent/US7384644B2/en
Priority to US11/341,955 priority patent/US20060127984A1/en
Priority to CY20061100421T priority patent/CY1105594T1/en
Priority to US11/508,797 priority patent/US7335364B2/en
Priority to US11/977,808 priority patent/US7923017B2/en
Priority to US11/999,127 priority patent/US7459270B2/en
Priority to US12/118,841 priority patent/US7897156B2/en
Priority to US12/200,176 priority patent/US7964395B2/en
Priority to US12/200,295 priority patent/US7964396B2/en
Priority to US12/471,144 priority patent/US7939086B2/en
Priority to US12/607,585 priority patent/US7892533B2/en
Priority to US12/836,324 priority patent/US7964398B2/en
Priority to US13/006,824 priority patent/US8372622B2/en
Priority to US13/009,636 priority patent/US8163293B2/en
Priority to US13/053,450 priority patent/US8268329B2/en
Priority to US13/053,361 priority patent/US8268325B2/en
Priority to US13/106,176 priority patent/US8236560B2/en
Priority to US13/422,028 priority patent/US20120183574A1/en
Priority to US13/544,201 priority patent/US8470598B2/en
Priority to US13/588,217 priority patent/US20120328650A1/en
Priority to BE2013C065C priority patent/BE2013C065I2/fr
Priority to FR13C0070C priority patent/FR13C0070I2/en
Priority to CY2013048C priority patent/CY2013048I1/en
Priority to HUS1600010C priority patent/HUS1600010I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and which is characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus or its recombinants as medicament or vaccine. Additionally, a method for inducing an immune response even in immuno-compromised patients, patients with pre-existing immunity to the vaccine virus or patients undergoing antiviral therapies is provided.
PCT/EP2001/013628 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant WO2002042480A2 (en)

Priority Applications (51)

Application Number Priority Date Filing Date Title
ES01991753.3T ES2256323T5 (en) 2000-11-23 2001-11-22 Variant of the Modified Vaccinia Ankara virus
UA2003054618A UA76731C2 (en) 2000-11-23 2001-11-22 Mva-bn strain of modified vaccinia ankara virus, pharmaceutical composition, vaccine, use of mva-bn strain for vaccine preparation, method for transfer of homologous and/or heterologous nucleic acid sequence into the target cells in vitro, method for preparing peptide or protein, method for obtaining mva-bn strain, host cell, set for primary/buster immunization
PL361459A PL212047B1 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
AU3163902A AU3163902A (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
DE60116371.0T DE60116371T3 (en) 2000-11-23 2001-11-22 VARIANT OF THE MODIFIED VACCINIA ANKARA VIRUS
CA2421151A CA2421151C (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
BRPI0115533A BRPI0115533B8 (en) 2000-11-23 2001-11-22 Variation of the modified vaccinia ankara virus
JP2002545184A JP4421188B2 (en) 2000-11-23 2001-11-22 Denatured vaccinia Ankara virus mutant
NZ524661A NZ524661A (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
IL15471201A IL154712A0 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
SI200130512T SI1335987T2 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
AT01991753T ATE314483T2 (en) 2000-11-23 2001-11-22 VARIANT OF MODIFIED VACCINIA ANKARA VIRUS
EP01991753.3A EP1335987B2 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
MXPA03002513A MXPA03002513A (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant.
KR1020037006970A KR100830295B1 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
HU0400685A HU230198B1 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
EEP200300173A EE05680B1 (en) 2000-11-23 2001-11-22 Modified vaccine virus, its preparation and use, pharmaceutical composition containing it and vaccine
AU2002231639A AU2002231639B2 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant
IL154712A IL154712A (en) 2000-11-23 2003-03-03 Modified vaccinia ankara virus variant
US10/418,854 US7097842B2 (en) 2000-11-23 2003-04-18 Modified vaccinia virus ankara for the vaccination of neonates
US10/440,073 US7189536B2 (en) 2000-11-23 2003-05-16 Modified vaccinia ankara virus variant
US10/439,439 US6913752B2 (en) 2000-11-23 2003-05-16 Modified Vaccinia Ankara virus variant
US10/439,953 US6761893B2 (en) 2000-11-23 2003-05-16 Modified vaccinia ankara virus variant
NO20032309A NO337867B1 (en) 2000-11-23 2003-05-21 Modified Vaccinia Ankara virus strain MVA-BN and derivatives thereof, methods for introducing nucleic acid sequence into target cells, preparation of peptide or protein and preparation of variant of MVA, cell containing the variant, immunization set and use of the variant.
HK04102348.1A HK1059453A1 (en) 2000-11-23 2004-03-31 Modified vaccinia ankara virus variant
US11/071,741 US7445924B2 (en) 2000-11-23 2005-03-03 Modified Vaccinia Ankara virus variant and cultivation method
US11/112,438 US7628980B2 (en) 2000-11-23 2005-04-22 Modified vaccinia virus ankara for the vaccination of neonates
US11/198,557 US7384644B2 (en) 2000-11-23 2005-08-05 Modified Vaccinia Ankara virus variant
US11/341,955 US20060127984A1 (en) 2000-11-23 2006-01-27 Modified Vaccinia virus Ankara for the vaccination of neonates
CY20061100421T CY1105594T1 (en) 2000-11-23 2006-03-27 VARIANT OF MODIFIED VACCINIA ANKARA VIRUS
US11/508,797 US7335364B2 (en) 2000-11-23 2006-08-23 Modified Vaccinia Ankara virus variant
US11/977,808 US7923017B2 (en) 2000-11-23 2007-10-26 Modified Vaccinia Ankara virus variant
US11/999,127 US7459270B2 (en) 2000-11-23 2007-12-04 Modified Vaccinia Ankara virus variant
US12/118,841 US7897156B2 (en) 2001-11-22 2008-05-12 Modified vaccinia virus ankara for the vaccination of neonates
US12/200,176 US7964395B2 (en) 2000-11-23 2008-08-28 Modified vaccinia ankara virus variant and cultivation method
US12/200,295 US7964396B2 (en) 2000-11-23 2008-08-28 Modified vaccinia ankara virus variant and cultivation method
US12/471,144 US7939086B2 (en) 2000-11-23 2009-05-22 Modified Vaccinia Ankara virus variant
US12/607,585 US7892533B2 (en) 2000-11-23 2009-10-28 Modified vaccinia virus ankara for the vaccination of neonates
US12/836,324 US7964398B2 (en) 2000-11-23 2010-07-14 Modified vaccinia ankara virus variant and cultivation method
US13/006,824 US8372622B2 (en) 2000-11-23 2011-01-14 Modified vaccinia virus ankara for the vaccination of neonates
US13/009,636 US8163293B2 (en) 2000-11-23 2011-01-19 Modified Vaccinia Virus Ankara for the vaccination of neonates
US13/053,450 US8268329B2 (en) 2000-11-23 2011-03-22 Modified Vaccinia ankara virus variant
US13/053,361 US8268325B2 (en) 2000-11-23 2011-03-22 Modified Vaccinia Ankara virus variant
US13/106,176 US8236560B2 (en) 2000-11-23 2011-05-12 Modified Vaccinia Ankara virus variant and cultivation method
US13/422,028 US20120183574A1 (en) 2000-11-23 2012-03-16 Modified vaccinia virus ankara for the vaccnation of neonates
US13/544,201 US8470598B2 (en) 2000-11-23 2012-07-09 Modified Vaccinia Ankara virus variant and cultivation method
US13/588,217 US20120328650A1 (en) 2000-11-23 2012-08-17 Modified vaccinia ankara virus variant
BE2013C065C BE2013C065I2 (en) 2000-11-23 2013-11-21
FR13C0070C FR13C0070I2 (en) 2000-11-23 2013-12-13 MODIFIED VARIANT OF ANKARA VACCINE VIRUS
CY2013048C CY2013048I1 (en) 2000-11-23 2013-12-23 VARIANT OF MODIFIED VACCINIA ANKARA VIRUS
HUS1600010C HUS1600010I1 (en) 2000-11-23 2016-02-29 Modified vaccinia ankara virus variant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001764 2000-11-23
DKPA200001764 2000-11-23

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10/418,854 Continuation-In-Part US7097842B2 (en) 2000-11-23 2003-04-18 Modified vaccinia virus ankara for the vaccination of neonates
US10/440,073 Continuation US7189536B2 (en) 2000-11-23 2003-05-16 Modified vaccinia ankara virus variant
US10/439,439 Continuation US6913752B2 (en) 2000-11-23 2003-05-16 Modified Vaccinia Ankara virus variant
US10/439,953 Continuation US6761893B2 (en) 2000-11-23 2003-05-16 Modified vaccinia ankara virus variant

Publications (2)

Publication Number Publication Date
WO2002042480A2 WO2002042480A2 (en) 2002-05-30
WO2002042480A3 true WO2002042480A3 (en) 2002-08-01

Family

ID=8159864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/013628 WO2002042480A2 (en) 2000-11-23 2001-11-22 Modified vaccinia ankara virus variant

Country Status (30)

Country Link
US (11) US7189536B2 (en)
EP (4) EP2204452A1 (en)
JP (1) JP4421188B2 (en)
KR (3) KR100830295B1 (en)
CN (2) CN101676389A (en)
AT (1) ATE314483T2 (en)
AU (2) AU2002231639B2 (en)
BE (1) BE2013C065I2 (en)
BR (1) BRPI0115533B8 (en)
CA (1) CA2421151C (en)
CY (2) CY1105594T1 (en)
CZ (1) CZ295808B6 (en)
DE (2) DE20122302U1 (en)
DK (1) DK1335987T4 (en)
EE (1) EE05680B1 (en)
ES (1) ES2256323T5 (en)
FR (1) FR13C0070I2 (en)
HK (1) HK1059453A1 (en)
HU (2) HU230198B1 (en)
IL (2) IL154712A0 (en)
LU (1) LU92311I2 (en)
MX (1) MXPA03002513A (en)
NO (1) NO337867B1 (en)
NZ (1) NZ524661A (en)
PL (1) PL212047B1 (en)
PT (1) PT1335987E (en)
RU (1) RU2290438C2 (en)
SI (1) SI1335987T2 (en)
UA (1) UA76731C2 (en)
WO (1) WO2002042480A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7053491B2 (en) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Therapeutic HPV vaccine combination

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
CZ295808B6 (en) * 2000-11-23 2005-11-16 Bavarian Nordic A/S Modified vaccinia Ankara virus variant
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82466C2 (en) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Method for intensification of chordopoxvirus amplification
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
DE60314823T3 (en) 2002-04-19 2017-11-16 Bavarian Nordic A/S MODIFIED VARIANT OF VACCINIA ANKARA VIRUS AS VACCINE FOR NEWBORN
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
ES2256747T3 (en) * 2002-05-16 2006-07-16 Bavarian Nordic A/S EXPRESSION OF GENES IN THE VIRUS OF THE MODIFIED VACCINE, USING THE ATI PROMOTER OF THE VIRUELA DE LA VACA.
CN102719408A (en) 2002-05-16 2012-10-10 巴法里安诺迪克有限公司 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
BRPI0313559B8 (en) 2002-09-05 2021-05-25 Bavarian Nordic As method for the cultivation of primary cells and for the amplification of viruses under serum-free conditions
DK1536015T3 (en) * 2003-11-24 2008-02-18 Bavarian Nordic As Promoters for expression in modified vaccinia virus Ankara
EP1757312B1 (en) * 2004-06-14 2011-01-19 Ishihara Sangyo Kaisha, Ltd. Freeze-dried composition of inactivated virus envelope with membrane fusion activity
CN1295339C (en) * 2005-01-11 2007-01-17 武汉大学 Attenuated vaccinia virus Tiantan strain vector and its preparation and application
NO347468B1 (en) * 2005-02-23 2023-11-13 Bavarian Nordic As A modified Vaccinia virus Ankara (MVA) for use in immunization.
WO2006113927A2 (en) * 2005-04-20 2006-10-26 University Of Washington Immunogenic vaccinia peptides and methods of using same
KR100717279B1 (en) * 2005-08-08 2007-05-15 삼성전자주식회사 Mask rom device and method of formimg the same
US7913477B2 (en) * 2006-01-27 2011-03-29 William Anthony Harper Insert registration in packets
EP1826264A1 (en) * 2006-02-24 2007-08-29 Deutsches Primatenzentrum GmbH Primate model for orthopox virus infections
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US20100129403A1 (en) 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
AU2007263280B2 (en) * 2006-06-20 2012-09-13 Transgene S.A. Process for producing poxviruses and poxvirus compositions
CA2662730A1 (en) * 2006-09-08 2008-03-13 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
CA2665068C (en) 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
JP2010526546A (en) 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ Purification of vaccinia virus and recombinant vaccinia virus vaccines
RU2499606C2 (en) * 2007-10-18 2013-11-27 Бавэариан Нордик Инк. Using mva (modified vaccinia ankara) for treating prostate cancer
KR100970449B1 (en) * 2007-12-21 2010-07-16 (주)이지아이 Safety rubber plate for children playground and construction method its
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
PL2382474T3 (en) 2009-01-20 2015-08-31 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
WO2011042180A1 (en) 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
AU2010321731B2 (en) * 2009-11-20 2017-01-05 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP5945270B2 (en) 2010-07-20 2016-07-05 バヴァリアン・ノルディック・アクティーゼルスカブ Method for collecting expression products
WO2012018856A2 (en) * 2010-08-02 2012-02-09 Virxsys Corporation Hiv vaccine therapy with concomitant antiviral monotherapy
EP2627774B1 (en) * 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
PL2739293T3 (en) * 2011-08-05 2020-11-16 Sillajen Biotherapeutics, Inc. Methods and compositions for production of vaccina virus
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EA029492B1 (en) 2012-07-10 2018-04-30 Трансген Са Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
SI2879702T1 (en) 2012-08-01 2020-02-28 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
CA2888367A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
PT2912183T (en) 2012-10-28 2020-06-05 Bavarian Nordic As Pr13.5 promoter for robust t-cell and antibody responses
SG11201507192SA (en) * 2013-03-15 2015-10-29 Bavarian Nordic As Single high dose of mva induces a protective immune response in neonates and infants
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10035832B2 (en) 2013-10-23 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
MY188100A (en) 2013-11-28 2021-11-18 Bavarian Nordic As Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
MX2016016533A (en) 2014-06-13 2017-05-01 Glaxosmithkline Biologicals Sa Immunogenic combinations.
WO2016036971A1 (en) 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
ES2777323T3 (en) 2014-09-03 2020-08-04 Bavarian Nordic As Methods and compositions for inducing protective immunity against filovirus infection
KR101971808B1 (en) 2014-09-26 2019-04-23 베쓰 이스라엘 디코니스 메디칼 센터 인크 Methods and Compositions for Inducing Protective Immunity Against Human Immunodeficiency Virus Infection
KR101645642B1 (en) 2014-10-16 2016-08-11 대한민국 Kvac recombinant vaccinia virus derived from kvac strain
KR101623498B1 (en) 2014-10-16 2016-05-24 대한민국 Kvacattenuated vaccinia virus kvac strain
AU2015341926B2 (en) 2014-11-04 2018-09-27 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN116173193A (en) 2015-04-17 2023-05-30 纪念斯隆凯特琳癌症中心 Use of MVA or MVA delta E3L as immunotherapeutic agent against solid tumors
IL255769B2 (en) 2015-05-20 2023-09-01 Broad Inst Inc Shared neoantigens
TW202241500A (en) 2015-06-09 2022-11-01 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
MX2017016273A (en) * 2015-06-15 2018-04-20 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine.
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
FR3042121A1 (en) 2015-10-08 2017-04-14 Jean-Marc Limacher ANTI-TUMOR COMPOSITION
CN106591361A (en) * 2015-10-20 2017-04-26 钱文斌 Recombinant pox oncolytic virus, and construction method and application thereof
TWI792091B (en) 2015-12-15 2023-02-11 荷蘭商傑森疫苗防護公司 Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
DK3407910T3 (en) 2016-01-29 2022-07-18 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) VACCINE AGAINST EQUINE ENCEPHALITIS VIRUS
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
MX2018010204A (en) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy.
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CN109219448B (en) 2016-06-16 2022-09-20 扬森疫苗与预防公司 HIV vaccine formulations
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
CN110494159A (en) 2016-09-02 2019-11-22 扬森疫苗与预防公司 Method of the induction for the immune response of HIV infection in the object of antiretroviral therapy
RS60919B1 (en) 2016-09-15 2020-11-30 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
JP7062003B2 (en) 2016-09-28 2022-05-02 バヴァリアン・ノルディック・アクティーゼルスカブ Compositions and Methods for Improving Transgene Stability in Poxvirus
EP3526332A1 (en) 2016-10-17 2019-08-21 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
ES2883720T3 (en) 2016-11-07 2021-12-09 Us Health Development of human papillomavirus agonist epitopes
BR112019011661A2 (en) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7406377B2 (en) 2017-05-15 2023-12-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Stable virus-containing composition
JP7272965B2 (en) 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Poxvirus vectors encoding HIV antigens and methods of use thereof
SG11202000112XA (en) 2017-07-19 2020-02-27 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019038388A1 (en) 2017-08-24 2019-02-28 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (en) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
MA51312A (en) 2017-12-19 2020-10-28 Bavarian Nordic As METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST THE HEPATITIS B VIRUS (HBV)
MX2020006225A (en) 2017-12-20 2020-12-07 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen constructs.
AU2019210189A1 (en) 2018-01-19 2020-08-06 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
WO2020014658A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CA3113818A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
EP3880694A1 (en) 2018-11-14 2021-09-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Tp5, a peptide inhibitor of aberrant and hyperactive cdk5/p25 as treatment for cancer
BR112021009856A8 (en) 2018-11-20 2021-09-08 Bavarian Nordic As Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
JP2022536137A (en) 2019-06-11 2022-08-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Mucosal vaccine formulation
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021099572A1 (en) 2019-11-20 2021-05-27 Bavarian Nordic A/S Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva)
EP4061406A1 (en) 2019-11-20 2022-09-28 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
WO2021150713A2 (en) 2020-01-21 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunogenic epitopes of h, k, and e human endogenous retroviruses (hervs)
US20230287067A1 (en) 2020-01-21 2023-09-14 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)
CA3170701A1 (en) 2020-03-12 2021-09-16 Bavarian Norcig A/S Compositions improving poxvirus stability
CA3181431A1 (en) 2020-06-10 2021-12-16 Jurgen Hausmann A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
CA3188801A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
EP4358999A1 (en) 2021-06-23 2024-05-01 Consejo Superior De Investigaciones Científicas Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
CA3230406A1 (en) 2021-09-03 2023-03-09 Jurgen Hausmann Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva)
WO2023118563A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003346A1 (en) 2022-06-30 2024-01-04 Bavarian Nordic A/S Mammalian cell line for the production of modified vaccinia virus ankara (mva)
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002355A1 (en) * 1995-07-04 1997-01-23 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Recombinant mva virus, and the use thereof
US5789245A (en) * 1993-09-15 1998-08-04 Chiron Corporation Alphavirus structural protein expression cassettes
WO2001068820A1 (en) * 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) * 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (en) * 1977-04-01 1978-10-05 Mayr Anton PREPARATION FOR TREATING HERPES ZOSTER AND OTHER HERPES INFECTIONS AND METHOD FOR THE PRODUCTION THEREOF
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
GB8322414D0 (en) * 1983-08-19 1983-09-21 Szelke M Renin inhibitors
FR2603040B1 (en) 1986-08-22 1990-01-26 Transgene Sa PROTEIN, DNA SEQUENCE, POXVIRUSES, CELLS AND THEIR CULTURE PROCESS, AS WELL AS THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USEFUL IN THE PREVENTION OF SCHISTOSOMOSIS
AU613583B2 (en) 1986-08-22 1991-08-08 Transgene S.A. Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
DE3743298A1 (en) 1987-12-19 1989-06-29 Wilkinson Sword Gmbh SHAVING APPARATUS AND METHOD FOR PRODUCING A LAYER OF LOW FRICTION RESISTANCE ON A SHAVING APPARATUS
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US6248333B1 (en) * 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
AU662491B2 (en) 1990-09-25 1995-09-07 Smithkline Beecham Corporation Medium for culture of mammalian cells
JP3602530B2 (en) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション Genetically engineered vaccine strain
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5490794A (en) * 1993-11-05 1996-02-13 Sumitomo Wiring Systems, Ltd. Branch joint box
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (en) † 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals
AU694519B2 (en) * 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2195642A1 (en) * 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
US5753489A (en) 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5566011A (en) * 1994-12-08 1996-10-15 Luncent Technologies Inc. Antiflector black matrix having successively a chromium oxide layer, a molybdenum layer and a second chromium oxide layer
ES2324745T3 (en) 1996-02-21 2009-08-13 Genetic Immunity Kft. PROCEDURES AND COMPOSITIONS FOR THE PROTECTIVE AND THERAPEUTIC GENETIC IMMUNIZATION.
WO1998004680A1 (en) 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
EP0951555A2 (en) † 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1998017283A1 (en) 1996-10-25 1998-04-30 The Wistar Institute Of Anatomy & Biology Method of vaccinating infants against infections
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
DE19729279A1 (en) † 1997-07-09 1999-01-14 Peter Hildebrandt Urological implant, in particular vascular wall support for the urinal tract
WO1999007869A1 (en) * 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
EP2042598A1 (en) 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
US6173813B1 (en) 1998-12-23 2001-01-16 Otis Elevator Company Electronic control for an elevator braking system
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
EP2388015A1 (en) * 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
KR100341030B1 (en) 2000-03-16 2002-06-20 유태욱 method for replaying caption data and audio data and a display device using the same
CA2409874A1 (en) 2000-05-24 2001-11-29 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
EP1303286B1 (en) * 2000-07-11 2006-04-26 Bayer HealthCare AG Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CZ295808B6 (en) † 2000-11-23 2005-11-16 Bavarian Nordic A/S Modified vaccinia Ankara virus variant
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82466C2 (en) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Method for intensification of chordopoxvirus amplification
EP1456230A2 (en) * 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
IL161526A0 (en) 2001-12-20 2004-09-27 Bavarian Nordic As Method for the recovery and purification of poxviruses from infected cells
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
DE60314823T3 (en) 2002-04-19 2017-11-16 Bavarian Nordic A/S MODIFIED VARIANT OF VACCINIA ANKARA VIRUS AS VACCINE FOR NEWBORN
ES2256747T3 (en) * 2002-05-16 2006-07-16 Bavarian Nordic A/S EXPRESSION OF GENES IN THE VIRUS OF THE MODIFIED VACCINE, USING THE ATI PROMOTER OF THE VIRUELA DE LA VACA.
CN102719408A (en) * 2002-05-16 2012-10-10 巴法里安诺迪克有限公司 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
BRPI0313559B8 (en) * 2002-09-05 2021-05-25 Bavarian Nordic As method for the cultivation of primary cells and for the amplification of viruses under serum-free conditions
AU2003293675B2 (en) * 2002-11-25 2009-04-23 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ATI promoters
US6976752B2 (en) * 2003-10-28 2005-12-20 Lexmark International, Inc. Ink jet printer with resistance compensation circuit
DK1536015T3 (en) * 2003-11-24 2008-02-18 Bavarian Nordic As Promoters for expression in modified vaccinia virus Ankara
EP1586330A1 (en) * 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
US8354093B2 (en) * 2004-10-15 2013-01-15 Washington University Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
CA2665068C (en) * 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
RU2499606C2 (en) * 2007-10-18 2013-11-27 Бавэариан Нордик Инк. Using mva (modified vaccinia ankara) for treating prostate cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789245A (en) * 1993-09-15 1998-08-04 Chiron Corporation Alphavirus structural protein expression cassettes
WO1997002355A1 (en) * 1995-07-04 1997-01-23 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Recombinant mva virus, and the use thereof
WO2001068820A1 (en) * 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENDER B. S. ET AL.: "ORAL IMMUNIZATION WITH A REPLICATION-DEFICIENT RECOMBINANT VACCINIAVIRUS PROTECTS MICE AGAINST INFLUENZA", JOURNAL OF VIROLOGY, vol. 70, no. 9, 1 September 1996 (1996-09-01), pages 6418 - 6424, XP002055082, ISSN: 0022-538X *
MEYER H. ET AL.: "MAPPING OF DELETIONS IN THE GENOME OF THE HIGHLY ATTENUATED VACCINIA VIRUS MVA AND THEIR INFUENCE ON VIRULENCE", JOURNAL OF GENERAL VIROLOGY, vol. 72, 1991, pages 1031 - 1038, XP000952390, ISSN: 0022-1317 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7053491B2 (en) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Therapeutic HPV vaccine combination

Also Published As

Publication number Publication date
CN101676389A (en) 2010-03-24
EP2204452A1 (en) 2010-07-07
US20050271688A1 (en) 2005-12-08
US6761893B2 (en) 2004-07-13
KR100830295B1 (en) 2008-05-16
CA2421151A1 (en) 2002-05-30
HUS1600010I1 (en) 2020-01-28
US7384644B2 (en) 2008-06-10
US20090169579A1 (en) 2009-07-02
HUP0400685A3 (en) 2004-10-28
CN1476483A (en) 2004-02-18
KR100910297B1 (en) 2009-08-03
HK1059453A1 (en) 2004-07-02
EP1598425A1 (en) 2005-11-23
NO20032309D0 (en) 2003-05-21
DK1335987T3 (en) 2006-04-24
BR0115533B1 (en) 2017-11-14
AU3163902A (en) 2002-06-03
IL154712A0 (en) 2003-10-31
JP4421188B2 (en) 2010-02-24
EP1335987B2 (en) 2016-06-15
PL212047B1 (en) 2012-08-31
NO20032309L (en) 2003-05-21
CA2421151C (en) 2013-07-02
SI1335987T1 (en) 2006-06-30
KR20030081333A (en) 2003-10-17
HU230198B1 (en) 2015-10-28
CN100537773C (en) 2009-09-09
JP2004514436A (en) 2004-05-20
BR0115533A (en) 2004-02-03
KR20090057335A (en) 2009-06-04
ES2256323T5 (en) 2016-11-21
US7939086B2 (en) 2011-05-10
US20120328650A1 (en) 2012-12-27
CZ20031366A3 (en) 2003-08-13
US20100119545A1 (en) 2010-05-13
HUP0400685A2 (en) 2004-07-28
MXPA03002513A (en) 2004-09-10
US8268329B2 (en) 2012-09-18
FR13C0070I2 (en) 2019-06-21
PL361459A1 (en) 2004-10-04
US20110182932A1 (en) 2011-07-28
SI1335987T2 (en) 2016-10-28
US20030215466A1 (en) 2003-11-20
BRPI0115533B8 (en) 2021-05-25
KR20080032016A (en) 2008-04-11
IL154712A (en) 2010-05-31
EE05680B1 (en) 2013-10-15
RU2290438C2 (en) 2006-12-27
DK1335987T4 (en) 2016-09-19
ES2256323T3 (en) 2006-07-16
UA76731C2 (en) 2006-09-15
US7459270B2 (en) 2008-12-02
FR13C0070I1 (en) 2014-01-17
DE20122302U1 (en) 2005-02-24
PT1335987E (en) 2006-05-31
EP2202315A1 (en) 2010-06-30
LU92311I2 (en) 2014-01-20
US20030202988A1 (en) 2003-10-30
EP1335987A2 (en) 2003-08-20
AU2002231639B2 (en) 2007-01-04
US7189536B2 (en) 2007-03-13
NZ524661A (en) 2005-03-24
CY2013048I2 (en) 2015-12-09
US20080089907A1 (en) 2008-04-17
US6913752B2 (en) 2005-07-05
US20110182933A1 (en) 2011-07-28
WO2002042480A2 (en) 2002-05-30
EE200300173A (en) 2003-06-16
US20060280758A1 (en) 2006-12-14
CY1105594T1 (en) 2010-07-28
EP1335987B1 (en) 2005-12-28
NO337867B1 (en) 2016-07-04
CY2013048I1 (en) 2015-12-09
DE60116371T3 (en) 2016-11-17
US7335364B2 (en) 2008-02-26
DE60116371T2 (en) 2006-09-07
US20030206926A1 (en) 2003-11-06
CZ295808B6 (en) 2005-11-16
DE60116371D1 (en) 2006-02-02
US7923017B2 (en) 2011-04-12
ATE314483T2 (en) 2006-01-15
BE2013C065I2 (en) 2021-01-29
US8268325B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
WO2002042480A3 (en) Modified vaccinia ankara virus variant
NO20045480L (en) Intergenic regions such as insertion sites in the vaccinia virus ankara genome (MVA)
WO2001068117A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
WO2006044923A3 (en) Yeast-based therapeutic for chronic hepatitis c infection
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
NZ547776A (en) Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
MXPA05005203A (en) Vaccine against hcv.
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
EP2552490A4 (en) Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
UA84667C2 (en) Vaccine directed against infection induced by herpes virus of marek's disease
WO2004070002A3 (en) Cell lines and host nucleic acid sequences related to infectious disease
WO2008127307A3 (en) Induction of an immune response against dengue virus using prime-boost approach
EA200301151A1 (en) VACCINE AGAINST NATURAL DASH
WO2004108756A3 (en) Sars coronavirus peptides and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2421151

Country of ref document: CA

Ref document number: 154712

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002231639

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200300227

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 291/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 524661

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002513

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10418854

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PV2003-1366

Country of ref document: CZ

Ref document number: 10439953

Country of ref document: US

Ref document number: 10440073

Country of ref document: US

Ref document number: 10439439

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001991753

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002545184

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037006970

Country of ref document: KR

Ref document number: 018194109

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2003118436

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500105

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: PV2003-1366

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001991753

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037006970

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 524661

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524661

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: PV2003-1366

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2001991753

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201642

Country of ref document: IL